Articles tagged with “hematologic-oncology”

Decnupaz FDA Approval: First CD123 ADC for BPDCN Therapy

Review the May 2026 FDA approval of Decnupaz (pivekimab sunirine), the first CD123-targeted ADC for BPDCN. Explores clinical efficacy and launch strategies.

40 min read

5/13/2026

decnupaz bpdcn pivekimab sunirine cd123 adc hematologic oncology fda approval antibody drug conjugate rare blood cancer

Beqalzi (Sonrotoclax) FDA Approval: BCL-2 Inhibitor for MCL

Examine the FDA accelerated approval of Beqalzi (sonrotoclax), the first BCL-2 inhibitor for relapsed mantle cell lymphoma, including efficacy and safety data.

40 min read

5/4/2026

beqalzi sonrotoclax mantle cell lymphoma mcl bcl-2 inhibitor hematologic oncology fda approval targeted therapy